34956--7/28/2006--SYNTHETIC_BLOOD_INTERNATIONAL

related topics

{product, liability, claim}

{product, candidate, development}

{property, intellectual, protect}

{stock, price, share}

{regulation, government, change}

{control, financial, internal}

{cost, operation, labor}

{personnel, key, retain}

{acquisition, growth, future}

{interest, director, officer}

{stock, price, operating}

We will need to raise additional capital to continue our business. We are currently a one product company, so our future depends on the success of that product. We are required to conduct additional clinical trials in the future, which are expensive and time consuming, and the outcome of the trials is uncertain. Our activities are and will continue to be subject to extensive government regulation, which is expensive and time consuming, and we won t be able to sell our product without regulatory approval. We are a development stage company without revenues or profits, which raises doubt about our ability to continue as a going concern. Presently we are focusing on developing Oxycyte, which is subject to a high level of technological risk. We are not certain that we will be able to manufacture Oxycyte commercially. There are significant competitors developing similar products. We do not have experience in the sale and marketing of medical products. We have a history of losses and our future profitability is uncertain. The market may not accept our product. Our patents and other proprietary rights may not protect our technology. Our viability will be affected if we incur product liability claims in excess of our insurance coverage. We depend on the services of a limited number of key personnel. Health care reform and controls on health care spending may limit the price we can charge for Oxycyte and the amount we can sell. Uncertainty of third-party reimbursement could affect our future profitability. Our stock price could be volatile and your investment could suffer a decline in value. There are a large number of shares that may be sold in the future in the public market, which may depress the market price of our common stock.

Full 10-K form ▸

34956--7/28/2006--SYNTHETIC_BLOOD_INTERNATIONAL_INC